CITY OF INDUSTRY, Calif., Nov. 9 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. announces that Dr. Cyndi Chen, Director of Research, attended a special luncheon to meet Dr. Shin-Yong Moon after The Howard A. and Audrey M. Schneidermann Distinguished Lecture in Modern Biology at the University of California, Irvine on November 4, 2005. Dr. Moon’s lecture, entitled “Embryonic Stem Cell Research Present and Future” drew tremendous attendance and excitement.
His lecture was informative in both discussing core scientific topics including current work in his lab and development of Stem Cell Research Center in Korea and the ethical issues surrounding stem cell research.
“It was an honor to meet Dr. Moon. His knowledge of the global future outlook of stem cell research and potential therapies of stem cells allowed us to gain insight to accelerating our company’s growth and our efforts of making California the leader in stem cell research,” said Dr. Cyndi Chen, Director of Research for U.S. BioDefense, Inc.
Dr. Shin-Yong Moon is a pioneer in human stem cell research. He is the Director of the Korean Stem Cell Research Center, which was established in July of 2002 and is supported by the Korean Ministry of Science and Technology. Moon and his colleague Dr. Woo Suk Hwang first gained worldwide attention in 2004 for successfully producing genetically defined human embryonic stem cells using a scientific technique called nuclear transfer (or “therapeutic cloning”). This year, they used that technique to produce stem cells that were genetic matches of patients with certain disorders and illnesses.
The associated Korean Embryonic Stem Cell Bank has established human embryonic stem (ES) cell lines, including patient-specific human embryonic stem cell lines. The successful derivation of these patient-specific ES cell lines opens the way for once-undreamed of treatments for long-term diseases such as diabetes and Parkinson’s. Their work also raises a number of important questions about how to pursue this tremendous scientific promise while protecting patients, research donors and society. In the lecture, Moon addresses these issues and discussed the future of stem cell research here and around the world.
Forward-Looking Statements
Included in this release are certain “forward-looking” statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding U.S. BioDefense’s financial performance. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to U.S. BioDefense’s brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in U.S. BioDefense’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
U.S. BioDefense, Inc. David Chin 626-961-0562 info@usbiodefense.com
U.S. BioDefense, Inc.
CONTACT: David Chin of U.S. BioDefense, Inc., +1-626-961-0562,info@usbiodefense.com
